Jochen Knolle
Fundador en Pharvaris GmbH .
Fortuna: 28 M $ al 31/05/2024
Origen de la red de primer grado Jochen Knolle.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 21 | |
TVM Capital GmbH
 TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management.
13
| Private Company | Investment Managers | 13 |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
Thermosome GmbH
 Thermosome GmbH Pharmaceuticals: MajorHealth Technology Thermosome GmbH develops novel drugs for solid tumors. Its technology is used for delivery of various active pharmaceutical ingredients with its application in localized diseases. The company was founded by Lars Lindner, Martin Hossan and Hansjoerg Eibl and is headquartered in Planegg, Germany.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
Charité Research Organisation GmbH
 Charité Research Organisation GmbH Miscellaneous Commercial ServicesCommercial Services Charité Research Organisation GmbH is a contract research organization that helps clients move development projects from first time in human to proof of concept as quickly and efficiently as possible. The private company is based in Berlin, Germany and was founded in 2005 by Frank Wagner, who has been the CEO since then. Charité Research Organisation offers scientific and regulatory consultancy, protocol development, routine laboratory, biomarker laboratory, imaging, project management, monitoring, data management, biostatistics, and medical writing services. The German company also provides world-leading patient and healthy volunteer recruitment capabilities and delivers the best value solution for early clinical development.
4
| Private Company | Miscellaneous Commercial Services | 4 |
Anchor Therapeutics, Inc.
 Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Jochen Knolle a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member Founder | |
Centogene AG
 Centogene AG Medical/Nursing ServicesHealth Services Centogene AG focuses on genetic and biochemical diagnostic testing services for rare hereditary disorders. The firm operates through the offices located in Freiburg, Dubai and Noida. The company was founded by Arndt Rolfs in 2006 and is headquartered in Rostock, Germany. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member | |
| MAGFORCE AG | Medical Specialties | Chairman Investor Relations Contact Director of Finance/CFO | |
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Doctorate Degree | |
| DBV TECHNOLOGIES | Pharmaceuticals: Major | Director/Board Member General Counsel | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
leon-nanodrugs GmbH
 leon-nanodrugs GmbH Pharmaceuticals: MajorHealth Technology leon-nanodrugs GmbH develops oral and parenteral drugs. The firm's services include nanotechnology in medicine, MJR technology, pipeline, partnering with leon and leon network. The company was founded by Wolfgang Beier and Cornelia Beier in 2011 and is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member | |
TVM Life Science Management GmbH
 TVM Life Science Management GmbH Miscellaneous Commercial ServicesCommercial Services Part of TVM Capital GmbH, TVM Life Science Management GmbH provides management services. The company is based in Munich, Germany. The CEO of the German company is Stefan Fischer. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Executive Officer | |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Kurma Partners SA
 Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
| Julius-Maximilians-Universität Würzburg | College/University | Masters Business Admin Undergraduate Degree | |
| ACER THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| AFFIMED N.V. | Biotechnology | Director/Board Member Director/Board Member | |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Biotechnology | Chief Executive Officer Director/Board Member | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| CENTOGENE N.V. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Methexis Genomics NV | Corporate Officer/Principal | ||
| TIGENIX NV | Medical Specialties | Corporate Officer/Principal | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Regensburg | College/University | Undergraduate Degree | |
Volastra Therapeutics, Inc.
 Volastra Therapeutics, Inc. BiotechnologyHealth Technology Volastra Therapeutics, Inc. develops novel therapies for patients with metastatic cancers. The company was founded by Lewis Cantley, Samuel Bakhoum and Olivier Elemento and is headquartered in Boston, MA. | Biotechnology | Director/Board Member | |
| H2 CORE AG | Electrical Products | Director of Finance/CFO | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal | |
Microbiotica Ltd.
 Microbiotica Ltd. BiotechnologyHealth Technology Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chairman | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
INIM Pharma AB
 INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Arthur D. Little, Inc.
 Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| TiGenix, Inc. | President | ||
Tusk Therapeutics SA
 Tusk Therapeutics SA Pharmaceuticals: MajorHealth Technology Tusk Therapeutics SA develops and manufactures therapeutic products. The private company is based in Luxembourg, Luxembourg. and has subsidiaries in Belgium. Luc Dochez has been the CEO of the Luxembourger company since 2015. | Pharmaceuticals: Major | Chief Executive Officer |
Estadísticas
Internacional
| Alemania | 16 |
| Estados Unidos | 10 |
| Países Bajos | 9 |
| Suecia | 5 |
| Francia | 4 |
Sectorial
| Health Technology | 33 |
| Consumer Services | 8 |
| Commercial Services | 7 |
| Health Services | 2 |
| Finance | 2 |
Operativa
| Director/Board Member | 234 |
| Corporate Officer/Principal | 81 |
| Independent Dir/Board Member | 47 |
| Chief Executive Officer | 43 |
| Chairman | 40 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Martijn Kleijwegt | 33 |
| Rémi Droller | 29 |
| Hubert Birner | 27 |
| Luc Dochez | 26 |
| Ricky Sun | 24 |
| Cynthia Lavoie | 23 |
| Berndt A. E. Modig | 23 |
| Johannes G. C. P. Schikan | 22 |
| Viviane Monges | 22 |
| Manfred Rüdiger | 22 |
| Michael Berendt | 20 |
| David Meeker | 19 |
| Richard Gaster | 17 |
| Robert Glassman | 16 |
| Alexandra Goll | 14 |
- Bolsa de valores
- Insiders
- Jochen Knolle
- Conexiones Empresas
